Factor Model (net +1.4)
Factor Model
net +1.4 3.3 / 10Three analysts raise BTSG targets to $46–$55
Watch: Monitor quarterly earnings for sustained specialty division growth rates and margin expansion—the upgrade thesis hinges on proving that acceleration is durable, not cyclical. A miss on specialty growth could reverse these gains fast.
TD Cowen, BMO Capital, and BTIG all upgraded BrightSpring Health Services in late January and early February 2026, citing strong specialty generics acceleration and durable growth across pharmacy and provider services. Price targets rose to $46–$55, with BTIG's $55 target representing a 27% jump from its prior $50 level. All three maintained Buy or Outperform ratings, crediting the company's competitive positioning and operator quality.
Synchronized upgrades from three marquee healthcare analysts suggest institutional confidence in BTSG's specialty generics business is shifting materially higher. The $4–$13 target increases reflect not just sentiment but concrete performance data that's resonating across the street.
Evidence
4 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when BTSG changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.